Introduction Despite the introduction of targeted agents leading to therapeutic advances,
clinical management of patients with metastatic colorectal cancer (mCRC) is still challenged …

In this post-genomic era, the individualization of chemotherapy through the study of
pharmacogenetics is becoming an ever attainable reality. Keys to individual variations in …

Pharmacogenetics plays a key role in personalized cancer treatment. Currently, the clinically
available pharmacogenetic markers for metastatic colorectal cancer (mCRC) are in genes …

The treatment scenario of colorectal cancer (CRC) has been evolving in recent years with
the introduction of novel targeted agents and new therapeutic strategies for the metastatic …

In recent years statements such “predictive biomarkers are urgently needed” have been the
unavoidable conclusion of almost all scientific papers, reviews, and experts' talks at major …

Pharmacogenetics plays a key role in personalized cancer treatment. Currently, the clinically
available pharmacogenetic markers for metastatic colorectal cancer (mCRC) are in genes …

Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …

The diagnosis and management of colorectal cancer (CRC) has been impacted by the
discovery and validation of a wide variety of biomarkers designed to facilitate a personalized …

Evolving intensiveness of colorectal cancer (CRC) treatment, including chemotherapeutics
and targeted agents associations, in adjuvant and metastatic CRC (MCRC) settings …

The response of metastatic colorectal cancer (mCRC) to the first-line conventional
combination therapy is highly variable, reflecting the elevated heterogeneity of the disease …